arrow
M

Maeve A. Lowery

Trinity College Dublin
H指数:46
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

KHYG-1 cells retain functionality following exposure to the tumour and omental microenvironments of patients with obesity-associated cancer

KHYG-1细胞在接触肥胖相关癌症患者的肿瘤和网膜微环境后仍保持功能

2026-09-180
OAAI
miRNA-34a-5p is a novel biomarker and modulator of the radioresponse in esophageal adenocarcinoma

miRNA-34a-5p是食管腺癌放射反应的新型生物标志物和调节因子

2026-09-010
OAAI
Pembrolizumab plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: 4.5-year follow-up from the randomized phase III KEYNOTE-859 study

帕博利珠单抗联合化疗作为HER2阴性晚期胃或胃食管结合部腺癌的一线治疗:来自随机III期KEYNOTE-859研究的4.5年随访

2026-09-010
OAAI
Size-exclusion chromatography as a clinically applicable method for extracellular vesicles collection as liquid biopsies shows potential diagnostic relevance and correlation with poorer outcome in common cancer types

尺寸排阻色谱法作为临床适用的细胞外囊泡液体活检收集方法,显示出潜在的诊断相关性并与常见癌症类型的较差预后相关

2026-08-010
OAAI
Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial

帕博利珠单抗联合曲妥珠单抗和化疗治疗HER2阳性晚期胃癌:来自随机KEYNOTE-811试验的健康相关生活质量分析

2025-09-300
OAAI
First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial

一线帕博利珠单抗联合化疗治疗HER2阴性胃或胃食管结合部腺癌:来自随机III期KEYNOTE-859试验的健康相关生活质量

2025-09-200
PRE
KEYNOTE-859 update: Pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer

KEYNOTE-859更新:帕博利珠单抗联合化疗治疗晚期HER2阴性胃或胃食管结合部(G/GEJ)癌

2024-12-010
PRE
Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial
2023-11-0159
OAAI
Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer
2021-11-2515
OAAI
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma
2021-09-1595
OAAI
Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes
2021-03-2342
OAAI